| Business Summary | | Immunomedics,
Inc.
is
a
biopharmaceutical
company
applying
innovative
proprietary
technology
in
antibody
selection,
modification
and
chemistry
to
the
development
of
products
for
the
detection
and
treatment
of
cancers
and
other
diseases.
Integral
to
these
products
are
highly
specific
monoclonal
antibodies
designed
to
deliver
radioisotopes,
chemotherapeutic
agents,
toxins,
dyes
or
other
substances
to
a
specific
disease
site
or
organ
system.
The
Company
currently
markets
and
sells
CEA-Scan
in
the
United
States,
and
CEA-Scan
and
LeukoScan
throughout
Europe
and
in
certain
other
markets
outside
the
United
States. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Immunomedics,
Inc.
is
engaged
in
researching,
developing,
manufacturing
and
marketing
biopharmaceutical
products,
particularly
antibody-based
diagnostics
and
therapeutics
for
cancer
and
infectious
diseases.
For
the
fiscal
year
ended
6/30/01,
revenues
increased
88%
to
$11.2
million.
Net
loss
applicable
to
Com.
decreased
53%
to
$4.8
million.
Revenues
reflect
increased
interest
income.
Lower
loss
benefitted
from
$803
thousand
in
income
tax
benefits. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Goldenberg, 62 Chairman | $994K | -- | Cynthia Sullivan, 44 Pres,
CEO, Director | 594K | $2.2M | Hans Hansen, 67 VP,
R&D | 90K | 1.7M | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|